Table 4.

Patient-specific decisions for two patients using data from a hypothetical phase 3 randomized controlled trial that reported a hazard ratio of 0.5, favoring superlumab over nivolumab across all International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic subgroups.

Parameter	Patient A		Patient B		Conclusions
IMDC prognostic subgroup	Favorable risk		Poor risk		The two patients differ only in their prognostic status
	Nivolumab	Superlumab	Nivolumab	Superlumab
Median overall survival (months)	18	36	2	4	The median and mean survival differences are more pronounced for patient A compared with patient B
Mean overall survival (months)	26	52	5.8	2.9
Survival probablity at 3 months	89%	94%	35%	60%	The absolute risk reduction at 3 months is more pronounced for patient B compared with patient A
Utilities based on the first joint utility function (Figure 5A and Table 2)	100	85	76	80	Choose nivolumab for patient A and superlumab for patient B
Utilities based on the second joint utility function (Figure 5B and Table 3)	96	109	62	56	Choose superlumab for patient A and nivolumab for patient B